Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 427 entries
View as:

A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04211558 Org: User:
Start: 08/12/20 End: 10/09/20 Due: 10/09/21

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

Phase: N/A Priority: Normal
NCT ID: NCT01029262 Org: User:
Start: 01/26/10 End: 05/09/18 Due: 05/09/19

A Research Study for Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00106418 Org: User:
Start: 05/07/03 End: 09/01/06 Due: 09/01/07

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06363630 Org: User:
Start: 04/23/24 End: 08/29/24 Due: 08/29/25

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT01566695 Org: User:
Start: 04/26/13 End: 12/21/23 Due: 12/21/24

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Phase: N/A Priority: Normal
NCT ID: NCT03743246 Org: User:
Start: 10/17/18 End: 01/26/24 Due: 01/26/25

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT03097016 Org: User:
Start: 03/30/17 End: 12/23/17 Due: 12/23/18

A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance

Phase: N/A Priority: Normal
NCT ID: NCT02849444 Org: User:
Start: 09/23/12 End: 12/10/20 Due: 12/10/21

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02733042 Org: User:
Start: 05/11/16 End: 08/21/22 Due: 08/21/23

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00407407 Org: User:
Start: 11/01/06 End: 02/01/08 Due: 02/01/09

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Phase: N/A Priority: Normal
NCT ID: NCT04958291 Org: User:
Start: 08/03/21 End: 12/07/21 Due: 12/07/22

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02164071 Org: User:
Start: 04/11/12 End: 07/04/15 Due: 07/04/16

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

Phase: N/A Priority: Normal
NCT ID: NCT01146574 Org: User:
Start: 06/30/10 End: 03/07/16 Due: 03/07/17

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02269943 Org: User:
Start: 02/13/15 End: 04/20/17 Due: 04/20/18

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04789655 Org: User:
Start: 06/16/21 End: 04/14/25 Due: 04/14/26

First Line Therapy for Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00456846 Org: User:
Start: 02/01/08 End: 05/31/13 Due: 05/31/14

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Phase: N/A Priority: Normal
NCT ID: NCT01456039 Org: User:
Start: 12/01/11 End: 12/14/18 Due: 12/14/19

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02435992 Org: User:
Start: 06/17/15 End: 06/17/20 Due: 06/17/21

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Phase: N/A Priority: Normal
NCT ID: NCT01099267 Org: User:
Start: 03/01/10 End: 10/01/10 Due: 10/01/11

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Phase: N/A Priority: Normal
NCT ID: NCT01835561 Org: User:
Start: 03/01/13 End: 08/21/14 Due: 08/21/15

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Phase: N/A Priority: Normal
NCT ID: NCT02192489 Org: User:
Start: 11/01/14 End: 06/30/17 Due: 06/30/18

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01712789 Org: User:
Start: 11/06/12 End: 12/11/19 Due: 12/11/20

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01177397 Org: User:
Start: 07/20/10 End: 12/09/16 Due: 12/09/17

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02635061 Org: User:
Start: 08/25/16 End: 01/22/24 Due: 01/22/25

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Phase: N/A Priority: Normal
NCT ID: NCT03682536 Org: User:
Start: 01/02/19 End: 09/28/27 Due: 09/28/28